AAPL317.31+1.99 (+0.63%) ▲|ABBV248.00-0.08 (-0.03%) ▼|ABT92.11-1.82 (-1.94%) ▼|ACN138.52+3.29 (+2.43%) ▲|ADBE230.61+6.97 (+3.12%) ▲|AMAT575.39-27.11 (-4.50%) ▼|AMD534.39-23.50 (-4.21%) ▼|AMGN360.45-2.94 (-0.81%) ▼|AMT169.50+0.91 (+0.54%) ▲|AMZN247.31+1.97 (+0.80%) ▲|AVGO384.05-15.92 (-3.98%) ▼|AXP354.43+3.85 (+1.10%) ▲|BA215.51-6.77 (-3.05%) ▼|BAC59.50-0.17 (-0.28%) ▼|BKNG175.80-2.59 (-1.45%) ▼|BLK1,031.56-4.55 (-0.44%) ▼|BMY59.34+1.76 (+3.06%) ▲|BNY151.27-0.65 (-0.43%) ▼|BRK-B496.85+3.14 (+0.64%) ▲|C140.71-0.08 (-0.06%) ▼|CAT931.47-20.94 (-2.20%) ▼|CL93.21+0.97 (+1.05%) ▲|CMCSA23.97+0.40 (+1.70%) ▲|COF203.02+1.50 (+0.74%) ▲|COP112.85+3.81 (+3.49%) ▲|COST926.43+10.18 (+1.11%) ▲|CRM171.22+7.90 (+4.84%) ▲|CSCO119.25-2.06 (-1.70%) ▼|CVS105.90+1.75 (+1.68%) ▲|CVX182.20+5.80 (+3.29%) ▲|DE585.64-1.22 (-0.21%) ▼|DHR200.16+1.11 (+0.56%) ▲|DIS96.00+0.38 (+0.40%) ▲|DUK126.86+1.38 (+1.10%) ▲|EMR135.38-3.50 (-2.52%) ▼|FDX313.74-0.95 (-0.30%) ▼|GD372.78-2.28 (-0.61%) ▼|GE353.42-5.85 (-1.63%) ▼|GEV1,042.60-48.97 (-4.49%) ▼|GILD131.40+1.57 (+1.21%) ▲|GM76.72-1.13 (-1.45%) ▼|GOOG350.67-4.36 (-1.23%) ▼|GOOGL352.51-4.67 (-1.31%) ▼|GS1,045.91-9.27 (-0.88%) ▼|HD337.11-6.19 (-1.80%) ▼|HON222.25-4.17 (-1.84%) ▼|IBM290.23+2.67 (+0.93%) ▲|INTC103.12-6.72 (-6.12%) ▼|INTU289.76+14.80 (+5.38%) ▲|ISRG407.12+0.34 (+0.08%) ▲|JNJ257.77+0.79 (+0.31%) ▲|JPM334.53-1.94 (-0.58%) ▼|KO84.25+0.76 (+0.91%) ▲|LIN524.06-5.73 (-1.08%) ▼|LLY1,181.87-6.71 (-0.56%) ▼|LMT520.68-2.54 (-0.49%) ▼|LOW207.70-3.93 (-1.86%) ▼|LRCX329.92-20.41 (-5.83%) ▼|MA537.70+10.96 (+2.08%) ▲|MCD272.61-1.99 (-0.72%) ▼|MDLZ59.86+1.03 (+1.75%) ▲|MDT83.57-0.30 (-0.36%) ▼|META656.73-12.48 (-1.86%) ▼|MMM157.70+0.18 (+0.11%) ▲|MO71.87+0.08 (+0.11%) ▲|MRK124.03+0.49 (+0.40%) ▲|MS221.09-1.19 (-0.54%) ▼|MSFT390.99+5.89 (+1.53%) ▲|MU937.00-42.30 (-4.32%) ▼|NEE88.38+0.42 (+0.48%) ▲|NFLX73.83+0.46 (+0.63%) ▲|NKE43.76-0.61 (-1.37%) ▼|NOW111.26+3.55 (+3.30%) ▲|NVDA203.53-7.43 (-3.52%) ▼|ORCL131.54-9.10 (-6.47%) ▼|PEP138.49+1.11 (+0.81%) ▲|PFE24.48+0.31 (+1.28%) ▲|PG148.37+1.33 (+0.90%) ▲|PLTR130.04+3.25 (+2.56%) ▲|PM180.19-1.43 (-0.79%) ▼|QCOM183.98-5.18 (-2.74%) ▼|RTX196.39+0.46 (+0.23%) ▲|SBUX107.34+1.33 (+1.25%) ▲|SCHW102.38-0.74 (-0.72%) ▼|SO96.47+0.86 (+0.90%) ▲|SPG219.49+0.72 (+0.33%) ▲|T21.55+0.42 (+1.99%) ▲|TMO528.51+1.46 (+0.28%) ▲|TMUS188.41+0.80 (+0.43%) ▲|TSLA394.76-13.00 (-3.19%) ▼|TXN298.57-12.89 (-4.14%) ▼|UBER74.26-0.28 (-0.38%) ▼|UNH429.09+4.47 (+1.05%) ▲|UNP289.13+2.17 (+0.76%) ▲|UPS112.89+0.42 (+0.37%) ▲|USB62.34-0.07 (-0.11%) ▼|V357.75+8.78 (+2.52%) ▲|VZ42.68+0.56 (+1.33%) ▲|WFC87.67+0.51 (+0.59%) ▲|WMT114.78+0.88 (+0.77%) ▲|XOM144.51+5.63 (+4.05%) ▲|AAPL317.31+1.99 (+0.63%) ▲|ABBV248.00-0.08 (-0.03%) ▼|ABT92.11-1.82 (-1.94%) ▼|ACN138.52+3.29 (+2.43%) ▲|ADBE230.61+6.97 (+3.12%) ▲|AMAT575.39-27.11 (-4.50%) ▼|AMD534.39-23.50 (-4.21%) ▼|AMGN360.45-2.94 (-0.81%) ▼|AMT169.50+0.91 (+0.54%) ▲|AMZN247.31+1.97 (+0.80%) ▲|AVGO384.05-15.92 (-3.98%) ▼|AXP354.43+3.85 (+1.10%) ▲|BA215.51-6.77 (-3.05%) ▼|BAC59.50-0.17 (-0.28%) ▼|BKNG175.80-2.59 (-1.45%) ▼|BLK1,031.56-4.55 (-0.44%) ▼|BMY59.34+1.76 (+3.06%) ▲|BNY151.27-0.65 (-0.43%) ▼|BRK-B496.85+3.14 (+0.64%) ▲|C140.71-0.08 (-0.06%) ▼|CAT931.47-20.94 (-2.20%) ▼|CL93.21+0.97 (+1.05%) ▲|CMCSA23.97+0.40 (+1.70%) ▲|COF203.02+1.50 (+0.74%) ▲|COP112.85+3.81 (+3.49%) ▲|COST926.43+10.18 (+1.11%) ▲|CRM171.22+7.90 (+4.84%) ▲|CSCO119.25-2.06 (-1.70%) ▼|CVS105.90+1.75 (+1.68%) ▲|CVX182.20+5.80 (+3.29%) ▲|DE585.64-1.22 (-0.21%) ▼|DHR200.16+1.11 (+0.56%) ▲|DIS96.00+0.38 (+0.40%) ▲|DUK126.86+1.38 (+1.10%) ▲|EMR135.38-3.50 (-2.52%) ▼|FDX313.74-0.95 (-0.30%) ▼|GD372.78-2.28 (-0.61%) ▼|GE353.42-5.85 (-1.63%) ▼|GEV1,042.60-48.97 (-4.49%) ▼|GILD131.40+1.57 (+1.21%) ▲|GM76.72-1.13 (-1.45%) ▼|GOOG350.67-4.36 (-1.23%) ▼|GOOGL352.51-4.67 (-1.31%) ▼|GS1,045.91-9.27 (-0.88%) ▼|HD337.11-6.19 (-1.80%) ▼|HON222.25-4.17 (-1.84%) ▼|IBM290.23+2.67 (+0.93%) ▲|INTC103.12-6.72 (-6.12%) ▼|INTU289.76+14.80 (+5.38%) ▲|ISRG407.12+0.34 (+0.08%) ▲|JNJ257.77+0.79 (+0.31%) ▲|JPM334.53-1.94 (-0.58%) ▼|KO84.25+0.76 (+0.91%) ▲|LIN524.06-5.73 (-1.08%) ▼|LLY1,181.87-6.71 (-0.56%) ▼|LMT520.68-2.54 (-0.49%) ▼|LOW207.70-3.93 (-1.86%) ▼|LRCX329.92-20.41 (-5.83%) ▼|MA537.70+10.96 (+2.08%) ▲|MCD272.61-1.99 (-0.72%) ▼|MDLZ59.86+1.03 (+1.75%) ▲|MDT83.57-0.30 (-0.36%) ▼|META656.73-12.48 (-1.86%) ▼|MMM157.70+0.18 (+0.11%) ▲|MO71.87+0.08 (+0.11%) ▲|MRK124.03+0.49 (+0.40%) ▲|MS221.09-1.19 (-0.54%) ▼|MSFT390.99+5.89 (+1.53%) ▲|MU937.00-42.30 (-4.32%) ▼|NEE88.38+0.42 (+0.48%) ▲|NFLX73.83+0.46 (+0.63%) ▲|NKE43.76-0.61 (-1.37%) ▼|NOW111.26+3.55 (+3.30%) ▲|NVDA203.53-7.43 (-3.52%) ▼|ORCL131.54-9.10 (-6.47%) ▼|PEP138.49+1.11 (+0.81%) ▲|PFE24.48+0.31 (+1.28%) ▲|PG148.37+1.33 (+0.90%) ▲|PLTR130.04+3.25 (+2.56%) ▲|PM180.19-1.43 (-0.79%) ▼|QCOM183.98-5.18 (-2.74%) ▼|RTX196.39+0.46 (+0.23%) ▲|SBUX107.34+1.33 (+1.25%) ▲|SCHW102.38-0.74 (-0.72%) ▼|SO96.47+0.86 (+0.90%) ▲|SPG219.49+0.72 (+0.33%) ▲|T21.55+0.42 (+1.99%) ▲|TMO528.51+1.46 (+0.28%) ▲|TMUS188.41+0.80 (+0.43%) ▲|TSLA394.76-13.00 (-3.19%) ▼|TXN298.57-12.89 (-4.14%) ▼|UBER74.26-0.28 (-0.38%) ▼|UNH429.09+4.47 (+1.05%) ▲|UNP289.13+2.17 (+0.76%) ▲|UPS112.89+0.42 (+0.37%) ▲|USB62.34-0.07 (-0.11%) ▼|V357.75+8.78 (+2.52%) ▲|VZ42.68+0.56 (+1.33%) ▲|WFC87.67+0.51 (+0.59%) ▲|WMT114.78+0.88 (+0.77%) ▲|XOM144.51+5.63 (+4.05%) ▲|

23.1 C

New York

Tuesday, July 14, 2026

Woven Woven Redefines Children’s Sleep Wellness with Innovative Bead-Free Weighted Blankets

Tineco’s World #1 Floor Cleaner Range Up To 46% Off For Amazon Prime Day

Focusing on On-Chain-Native Prediction Markets: BM Wallet Launches Prediction Markets, Reimagining the Web3 User Experience

Tag: press

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi^® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI^® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.

SuperCom Signs New Contract with Southeastern Electronic Monitoring Service Provider to Boost U.S. Market Expansion

9th new service provider since mid-2024, this one to introduce SuperCom's Electronic Monitoring technology into Florida and Mississippi TEL AVIV, Israel, June 6, 2025...

Special Olympics Southern California Partners with Zum for Transportation for Summer Games Championship

Modern Transportation Leader Will Provide Safe, Reliable Bus Service During June 7-8 Event REDWOOD CITY, Calif., June 6, 2025 /PRNewswire/ -- Special Olympics Southern California...

Academy Sports + Outdoors Announces Quarterly Cash Dividend

KATY, Texas, June 6, 2025 /PRNewswire/ -- Academy Sports and Outdoors, Inc. (the "Company" or "Academy") (Nasdaq: ASO) announced today that on June 5,...

The Mom’s Choice Awards Names The Tales of Charlie Wags: New York City and The Tales of Charlie Wags: London, Among the Best in...

PHILADELPHIA, June 6, 2025 /PRNewswire/ -- Kendam Press is honored to announce that the New York and Paris titles in the Charlie Wags series has...

Maybacks Global Entertainment, LLC and Plex Sign Global Licensing and Distribution Agreement

MORRISTOWN, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN -- Maybacks Global Entertainment, LLC, a wholly owned subsidiary of Authentic Holdings, Inc. (OTC:AHRO), has signed a Licensing and Distribution Agreement with Plex GmbH ("Plex").

HIGH LINER FOODS ACQUIRES LEADING U.S. BREADED AND BATTERED SEAFOOD BRANDS MRS. PAUL’S AND VAN DE KAMP’S FROM CONAGRA BRANDS, INC. FOR USD $55...

Transaction secures existing contract manufacturing business bringing incremental volume, margin, synergies and growth opportunitiesEstimated to deliver USD $11 million annual run rate Adjusted EBITDA1...

METALLIS INCREASES NON-BROKERED PRIVATE PLACEMENT TO $1.7 MILLION

VANCOUVER, BC, June 6, 2025 /CNW/ - Metallis Resources Inc. (TSXV: MTS) (OTCQB: MTLFF) (the "Company" or "Metallis") announces that due to high demand, it has...

Willis Lease Finance Corporation Announces Pricing of $596.0 Million in Fixed Rate Notes

COCONUT CREEK, Fla., June 06, 2025 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), the leading lessor of commercial aircraft engines and global provider of aviation services, announced today that its wholly-owned subsidiary, Willis Engine Structured Trust VIII (“WEST”), has priced $524,000,000 in aggregate principal amount of Series A Fixed Rate Notes (the “Series A Notes”) and $72,000,000 in aggregate principal amount of Series B Fixed Rate Notes (the “Series B Notes” and, together with the Series A Notes, the “Notes”). The Notes will be secured by, among other things, WEST’s direct and indirect interests in a portfolio of 62 aircraft engines and two airframes, which WEST will acquire from WLFC or its other subsidiaries pursuant to an asset purchase agreement. The planned closing date is June 18, 2025.

SABINE ROYALTY TRUST ANNOUNCES MONTHLY CASH DISTRIBUTION FOR JUNE 2025

DALLAS, June 6, 2025 /PRNewswire/ -- Argent Trust Company, as Trustee of the Sabine Royalty Trust (NYSE: SBR), today declared a cash distribution to the...

DeFi Dev Corp. Partners with Drift Protocol to List dfdvSOL Liquid Staking Token

BOCA RATON, FL, June 06, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced a strategic partnership with Drift Protocol, the leading decentralized derivatives exchange on Solana with $1B in deposits.

EAT & BEYOND ANNOUNCES MARIO NAWFAL AS STRATEGIC ADVISOR

VANCOUVER, BC, June 06, 2025 (GLOBE NEWSWIRE) -- Eat & Beyond Global Holdings Inc. (CSE: EATS) (OTCPK: EATBF) (FSE: 988) (“Eat & Beyond” or the “Company”), is pleased to announce that that globally recognized entrepreneur, investor, and citizen journalist Mario Nawfal has joined the Company as a Strategic Advisor.

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –

Meala Partners with dsm-firmenich to Commercialize Texturizing Protein for Meat Alternatives

PB Pea protein, a high-performance texturizer is ready for market release in Europe, bringing cleaner labels and better nutritional value to meat alternatives HAIFA, Israel,...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsPress